These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25552881)

  • 21. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
    Bainey KR; Rahim S; Etherington K; Rokoss ML; Natarajan MK; Velianou JL; Brons S; Mehta SR;
    Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study.
    Yang JH; Hahn JY; Song YB; Choi SH; Choi JH; Lee SH; Jeong MH; Choi DJ; Park JS; Park HS; Gwon HC
    BMJ; 2014 Nov; 349():g6650. PubMed ID: 25398372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fimasartan, a novel angiotensin II receptor antagonist.
    Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
    Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valsartan after myocardial infarction.
    Güleç S
    Anadolu Kardiyol Derg; 2014 Dec; 14 Suppl 2():S9-13. PubMed ID: 25604205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Lam CS; McEntegart M; Claggett B; Liu J; Skali H; Lewis E; Køber L; Rouleau J; Velazquez E; Califf R; McMurray JJ; Pfeffer M; Solomon S
    Eur J Heart Fail; 2015 Mar; 17(3):301-12. PubMed ID: 25655011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Effect of Fimasartan in a Rat Model of Myocardial Infarction Evaluated by Cardiac Positron Emission Tomography with [
    Park H; Kim HS; Hong YJ; Min JJ; Kim HB; Kim MC; Sim DS; Kim JH; Kim DY; Lee JS; Ahn Y; Jeong MH
    Chonnam Med J; 2019 May; 55(2):109-115. PubMed ID: 31161123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
    Sebeková K; Lill M; Boor P; Heidland A; Amann K
    Am J Nephrol; 2009; 29(3):164-70. PubMed ID: 18753741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of angiotensin receptor blocker and angiotensin-coverting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study].
    Wang L; Huang XS; Zhou YL; Chen JY; Lin SG
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):967-71. PubMed ID: 16109551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model.
    Wang L; Cai SR; Zhang CH; He YL; Zhan WH; Wu H; Peng JJ
    Chin Med J (Engl); 2008 Nov; 121(21):2167-71. PubMed ID: 19080179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.
    Messadi-Laribi E; Griol-Charhbili V; Pizard A; Vincent MP; Heudes D; Meneton P; Alhenc-Gelas F; Richer C
    J Pharmacol Exp Ther; 2007 Oct; 323(1):210-6. PubMed ID: 17636004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aging-related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model: effect of early therapy with an angiotensin II type 1 receptor blocker.
    Jugdutt BI; Jelani A; Palaniyappan A; Idikio H; Uweira RE; Menon V; Jugdutt CE
    Circulation; 2010 Jul; 122(4):341-51. PubMed ID: 20625108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-receptor expression and IP3 receptor and PKCepsilon proteins.
    Xu Y; Menon V; Jugdutt BI
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):184-95. PubMed ID: 11967812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin blockade inhibits osteopontin expression in non-infarcted myocardium after myocardial infarction.
    Kusuyama T; Yoshiyama M; Omura T; Nishiya D; Enomoto S; Matsumoto R; Izumi Y; Akioka K; Takeuchi K; Iwao H; Yoshikawa J
    J Pharmacol Sci; 2005 Jul; 98(3):283-9. PubMed ID: 15997171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study.
    Oh GC; Joo KW; Kim MA; Choi DJ; Kim YJ; Lee HY
    Drug Des Devel Ther; 2020; 14():1341-1349. PubMed ID: 32308367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardioprotective effect of substance P in a porcine model of acute myocardial infarction.
    Sim DS; Kim W; Lee KH; Song HC; Kim JH; Park DS; Lim KS; Woo JS; Hong YJ; Ahn Y; Hong HS; Son Y; Jeong MH
    Int J Cardiol; 2018 Nov; 271():228-232. PubMed ID: 29884290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between myocardial flow reserve by oxygen-15 water positron emission tomography in the subacute phase of myocardial infarction and left ventricular remodeling in the chronic phase.
    Ohara M; Yukiiri K; Masugata H; Iwado Y; Takinami H; Nishiyama Y; Ohkawa M; Senda S; Ohmori K; Kohno M
    Hypertens Res; 2008 Jul; 31(7):1307-13. PubMed ID: 18957800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
    Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A
    Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fimasartan: A New Angiotensin Receptor Blocker.
    Lee HY; Oh BH
    Drugs; 2016 Jul; 76(10):1015-22. PubMed ID: 27272555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.